Analysts forecast that Nektar Therapeutics (NASDAQ:NKTR – Get Rating) will announce $22.96 million in sales for the current quarter, according to Zacks. Six analysts have issued estimates for Nektar Therapeutics’ earnings, with estimates ranging from $21.10 million to $26.25 million. Nektar Therapeutics reported sales of $28.33 million in the same quarter last year, which would […]
Bolt Biotherapeutics (NASDAQ:BOLT – Get Rating) and Nektar Therapeutics (NASDAQ:NKTR – Get Rating) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, dividends, earnings and profitability. Risk & Volatility Bolt Biotherapeutics has a beta of […]
Analysts expect that Nektar Therapeutics (NASDAQ:NKTR – Get Rating) will post earnings per share of ($1.00) for the current quarter, Zacks reports. Six analysts have provided estimates for Nektar Therapeutics’ earnings, with the lowest EPS estimate coming in at ($1.16) and the highest estimate coming in at ($0.67). Nektar Therapeutics posted earnings of ($0.69) per […]
Analysts forecast that Nektar Therapeutics (NASDAQ:NKTR – Get Rating) will report $23.05 million in sales for the current quarter, according to Zacks Investment Research. Six analysts have issued estimates for Nektar Therapeutics’ earnings. The highest sales estimate is $26.60 million and the lowest is $21.29 million. Nektar Therapeutics reported sales of $28.33 million during the […]
Shares of Nektar Therapeutics (NASDAQ:NKTR – Get Rating) have been given a consensus rating of “Hold” by the fifteen brokerages that are presently covering the firm, Marketbeat.com reports. Two research analysts have rated the stock with a sell recommendation, eight have assigned a hold recommendation and four have issued a buy recommendation on the company. […]